Patents by Inventor Avraham Yaron

Avraham Yaron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for modulating activation of NF-?B
    Patent number: 8263326
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-KB
    Publication number: 20090233855
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B? Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: August 8, 2008
    Publication date: September 17, 2009
    Inventors: Anthony M. MANNING, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Compounds and methods for modulating activation of NF-?B
    Patent number: 7414120
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: August 19, 2008
    Assignee: Signal Pharmaceuticals
    Inventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Compounds and methods for modulating activation of NF-kappaB
    Publication number: 20070208167
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: January 25, 2007
    Publication date: September 6, 2007
    Inventors: Anthony Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Compounds and methods for modulating activation of NF-?B
    Patent number: 7186503
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: March 6, 2007
    Assignee: Signal Pharmaceuticals LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of i?b
    Patent number: 6905836
    Abstract: Compounds that inhibit ubiquitin-mediated proteolysis of phosphorylated I?B by interfering, directly or indirectly, with the ability of ?-TrCP/E3RS to engage in protein-protein association involving hnRNP-U, are useful as drugs for treating conditions associated with NF-?B activation. Cellular and non-cellular screening methods for identifying such compounds are based on monitoring the association/dissociation of ?-TrCP/E3RS.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: June 14, 2005
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yinon Ben-Neriah, Irit Alkalay-Snir, Ada Hatzubai, Etti Ben Shushan, Matti Davis, Avraham Yaron
  • Compounds and methods for modulating activation of NF-kappaB
    Publication number: 20040203098
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: September 19, 2003
    Publication date: October 14, 2004
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkappaB
    Publication number: 20040014026
    Abstract: Compounds that inhibit ubiquitin-mediated proteolysis of phosphorylated I&kgr;B by interfering, directly or indirectly, with the ability of &bgr;-TrCP/E3RS to engage in protein-protein association involving hnRNP-U, are useful as drugs for treating conditions associated with NF-&kgr;B activation. Cellular and non-cellular screening methods for identifying such compounds are based on monitoring the association/dissociation of &bgr;-TrCP/IE3RS.
    Type: Application
    Filed: February 10, 2003
    Publication date: January 22, 2004
    Inventors: Yinon Ben-Neriah, Irit Alkalay-Snir, Ada Hatzubai, Etti Ben Shushan, Matti Davis, Avraham Yaron
  • Compounds and methods for modulating activation of NF-&kgr;B
    Patent number: 6656713
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: December 2, 2003
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Compounds and methods for modulating activation of NF-kB
    Publication number: 20030166587
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: April 9, 2001
    Publication date: September 4, 2003
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Compositions and methods for modulating cellular NF-.kappa.B activation
    Patent number: 5932425
    Abstract: Compositions and methods for modulating the activation of nuclear factor .kappa.B (NF-.kappa.B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I.kappa.B.alpha. and/or I.kappa.B.beta.. Such compositions may be used for treating diseases associated with NF-.kappa.B activation. Modulating agents include peptides that comprise a recognition domain for E3 ubiquitin ligase.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: August 3, 1999
    Assignees: Signal Pharmaceuticals, Inc., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Irit Alkalay, Yinon Ben-Neriah, Aaron Ciechanover, Anthony Manning, Frank Mercurio, Avraham Yaron